CLOSED STUDIES / Ovarian Cancer
GEICO 0901 / AGO-OVAR 16
Phase III study to evaluate the efficacy and safety of pazopanib as monotherapy versus placebo amongst women with epithelial ovarian, fallopian tube or primary peritoneal cancer who have not progressed after first-line chemotherapy.
Dr. José María del Campo
Inclusion Closing Date